Skip to content
Sample Page
Author:
Bio-Thera Solutions, Ltd
Posted Date:
July 23, 2026
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8013, an Antibody Drug Conjugate Targeting CD25 for the Treatment of Advanced Solid Tumors
Bio-Thera Solutions, Ltd
July 23, 2026
Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States
Bio-Thera Solutions, Ltd
May 18, 2026
Bio-Thera Solutions Announces Further Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), through Exclusive Commercialization and License Agreement in India
Bio-Thera Solutions, Ltd
March 23, 2026
